678 stories from 28 sources
The month in Medicine and Healthcare
Longest running story: 26 days
Click on a headline to see stories that shaped it.
Threads
8 threads
The Ebola outbreak expanded across the DRC every week, becoming the country’s deadliest outbreak and reaching new zones despite rising vaccination efforts. By month’s end, uncertain vaccine performance, limited doses, conflict, mistrust, and weak surveillance still constrained containment.
The administration advanced a narrower childhood vaccine policy while repeating a disproven vaccine-autism claim, and falling MMR coverage increased measles risk. Two Pennsylvania deaths and the highest US measles case count since domestic elimination gave the political dispute more immediate consequences.
Lilly strengthened its obesity-drug lead as competitors struggled, new pills showed promise, and demand reached unapproved versions of experimental treatments. Yet high prices, coverage withdrawals, Medicare exclusions, stigma, and physician reluctance kept expanding use from becoming broad access.
Clinical AI progressed from stakeholder consultations to treatment flags, prior authorization, care pathways, reimbursement, and hospital automation. The FDA then began building a broader oversight structure, while questions about accuracy, bias, validation, and accountability remained unresolved.
The Cyclospora outbreak grew past 10,000 illnesses and continued rising even after officials declared it contained. The outbreak, alongside an unusually high number of food recalls, exposed gaps in tracing, reporting, inspection, and response capacity.
War and siege disrupted cancer diagnosis, treatment, medicines, and follow-up care across Gaza, while oxygen shortages threatened premature babies and critically ill patients. By the following week, one hospital had run out of cancer medicines entirely, turning interrupted care into immediate risks of preventable death.
Moderna and Merck’s personalized mRNA vaccine cleared repeated late-stage melanoma milestones and strengthened the case for therapeutic cancer vaccines. Approval, durability, manufacturing complexity, pricing, and broader effectiveness still separate the result from routine care.
The administration’s expected FDA nominee became formal, while new CDC leadership began signaling different priorities and a changing relationship with scientific staff. Those appointments could reshape approval standards, enforcement, drug safety, and public-health policy.
Week’s Recap